I understand the point you're making, but my point is that the partnership terms that are generally entered into with small companies and BP involve large up front payments by BP to fund the development of the drug, followed by large royalties for the BP - often the majority of revenue - upon approval and marketing. This makes sense usually. BP is taking financial risk in the development of an early stage drug, and needs to be rewarded on the back end. I'm speculating, but it's unlikely that a BP is going to be all that eager to enter a partnership with royalty terms that reflect the reality of this situation:
1) CYDY has incurred substantially all financial risk regarding drug development, particularly once a BLA is accepted for combo.
2) The BP would be taking little financial risk, and would essentially just be providing sales and marketing.
If the company wants partnership terms reflective of the risk balance - namely, CYDY 99% of the risk, BP 1% of the risk - they're likely going to need to have a viable option forward without begging BP for sales help. Or at least a good bluff. With revenue and/or financing via licensing of the diagnostic, something like that, I still don't understand the difficulty of building a sales force. Clearly, other companies have successfully done it in the past.
And again, I'm still not suggesting that this is the preferred way forward. I'd love to see a great licensing or partnership deal on Monday morning. But I'd still rather the company have a strategy to pursue this path if nobody wants to offer partnership terms reflective of the risk incurred.
